Cancer immunotherapies: advances and bottlenecks.
Rui R, Zhou L, He S.
Front Immunol. 2023 Aug 24;14:1212476. doi: 10.3389/fimmu.2023.1212476. eCollection 2023.
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.
Huang Y, Hong W, Wei X.
J Hematol Oncol. 2022 Sep 8;15(1):129. doi: 10.1186/s13045-022-01347-8.
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment.
Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, Ping Y, Zhang Y.
J Hematol Oncol. 2021 Nov 6;14(1):187. doi: 10.1186/s13045-021-01200-4.
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.
Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S, Xiao M.
Mol Cancer. 2023 Mar 11;22(1):48. doi: 10.1186/s12943-023-01744-8.
Immunosenescence: a key player in cancer development.
Lian J, Yue Y, Yu W, Zhang Y.
J Hematol Oncol. 2020 Nov 10;13(1):151. doi: 10.1186/s13045-020-00986-z.
Turning cold tumors hot: from molecular mechanisms to clinical applications.
Zhang J, Huang D, Saw PE, Song E.
Trends Immunol. 2022 Jul;43(7):523-545. doi: 10.1016/j.it.2022.04.010. Epub 2022 May 25.
cGAS-STING pathway in cancer biotherapy.
Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X.
Mol Cancer. 2020 Sep 4;19(1):136. doi: 10.1186/s12943-020-01247-w.
The theory of tumor ecosystem.
Chen X, Song E.
Cancer Commun (Lond). 2022 Jul;42(7):587-608. doi: 10.1002/cac2.12316. Epub 2022 Jun 1.
Current Immunotherapies for Glioblastoma Multiforme.
Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H.
Front Immunol. 2021 Mar 9;11:603911. doi: 10.3389/fimmu.2020.603911. eCollection 2020.
(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy.
Ashrafizadeh M, Zarrabi A, Bigham A, Taheriazam A, Saghari Y, Mirzaei S, Hashemi M, Hushmandi K, Karimi-Maleh H, Nazarzadeh Zare E, Sharifi E, Ertas YN, Rabiee N, Sethi G, Shen M.
Med Res Rev. 2023 Nov;43(6):2115-2176. doi: 10.1002/med.21971. Epub 2023 May 11.
